search
Back to results

PROstaTe Cancer - Exercise-STudy (PRO-TEST) (PRO-TEST)

Primary Purpose

Prostate Cancer

Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
High Intensity Interval Training
Usual Care Observational Control
Sponsored by
Rigshospitalet, Denmark
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Prostate Cancer focused on measuring Prostate cancer, Localized, Exercise, Physical activity, Natural killer cells, Immune cells

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Pathologically verified localized prostate cancer
  • Eligible for curative radical prostatectomy

Exclusion Criteria:

  • Any other known malignancy requiring active treatment
  • Performance status > 1
  • Ongoing treatment with beta blockers
  • Physical disabilities precluding physical testing and/or exercise
  • Inability to read and understand Danish

Sites / Locations

  • Center for Physical Activity Research, Copenhagen University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

High Intensity Interval Training

Usual Care Observational Control

Arm Description

The HIIT-group will receive usual care plus a supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes.

Patients randomized to usual care control will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.

Outcomes

Primary Outcome Measures

Variability in intratumoral Natural Killer (NK)-cell infiltration
Natural killer (NK)-cell infiltration will be quantified using histological analyses.

Secondary Outcome Measures

Tumor vessel morphology
Tumor vessel morphology will be evaluated using histological analyses.
Tumor-metabolism, - biology and signaling
Tumor samples will undergo proteomic analyzes in order to uncover potential upregulated biomarkers.
Changes in immune cells
Quantification of immune cells will be measured in blood samples by flowcytometry analyses.
Changes in epinephrine concentration
Concentrations of epinephrine will be measured in blood samples by radioimmunoassay analyses.
Changes in nor-epinephrine concentration
Concentrations of nor-epinephrine will be measured in blood samples by radioimmunoassay analyses.
Changes in IL-1 concentration
Concentrations of IL-1 (Interleukin 1) will be measured in blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
Changes in IL- 2 concentration
Concentrations of IL-2 (Interleukin 2) will be measured in fasting blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
Changes in IL- 6 concentration
Concentrations of IL-6 (Interleukin 6) will be measured in fasting blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
Changes in IL- 8 concentration
Concentrations of IL-8 (Interleukin 8) will be measured in fasting blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
Changes in IL- 10 concentration
Concentrations of IL-10 (Interleukin 10) will be measured in fasting blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
Changes in IL- 15R alpha complex concentration
Concentrations of IL- 15Rα (IL- 15 receptor alpha) complex will be measured in blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
Changes in Tumor Necrosis Factor alpha (TNFa) concentration
Concentrations of TNFa will be measured in blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
Changes in Interferon Gamma (IFNγ) concentration
Concentrations of IFNγ will be measured in blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
Changes in Plasma Total-Cholesterol concentrations
Concentrations of total cholesterol will be measured in fasting blood samples by standard laboratory methods.
Changes in Plasma LDL-Cholesterol concentrations
Concentrations of LDL-cholesterol will be measured in fasting blood samples by standard laboratory methods
Changes in Plasma HDL-Cholesterol concentrations
Concentrations of HDL-cholesterol will be measured in fasting blood samples by standard laboratory methods
Changes in Plasma Triglyceride concentrations
Concentrations of triglycerides will be measured in fasting blood samples by standard laboratory methods
Changes in HbA1C (fasting blood samples)
Concentrations of HbA1C will be measured in fasting blood samples by standard laboratory methods
Changes in insulin
Concentrations of Insulin will be measured in fasting blood samples by standard laboratory methods
Change in body composition
Body weight and anthropometrics (height, waist and hip circumference) will be assessed using standard procedures. Resting heart rate and blood pressure (Microlife, BPA100) will be determined in a supine position. Body composition (fat mass, bone mass and fat-free mass) and bone mineral density are analyzed by whole-body dual-energy X-ray absorptiometry (DXA) scan (Lunar, Lunar Corporation Madison, Wisconsin, USA). Transverse scans at 1 cm intervals are made from head to toe measuring the absorption of x-ray beams at two different energy levels as these are sent through the body. Since the different chemical compounds in the body absorb the intensity of the X-rays differently, the scan allows for a valid determination of bone mass, fat mass and fat-free/bone-free mass
Change in VO2peak
The participants will undergo a maximal graded exercise test on a bicycle ergometer for evaluation of cardiovascular function and determination of the peak oxygen uptake (VO2peak). The test starts with a 5 min warm up at 70 watt (the watts may have to be adjusted to the individual fitness level). Warm up is immediately followed by a 20 watt increase every 1 min until exhaustion. Ventilation and expired gases will be measured during the test via an indirect calorimetric system, and heart rate will be assessed simultaneously.
Change in wattmax
The participants will undergo a maximal graded exercise test on a bicycle ergometer for evaluation of cardiovascular function and determination of the maximum watt (wattmax). The test starts with a 5 min warm up at 70 watt (the watts may have to be adjusted to the individual fitness level). Warm up is immediately followed by a 20 watt increase every 1 min until exhaustion. The maximum watt will be calculated.
Changes in patient-reported Quality of Life - FACT
Patient reported quality of life is measured by Functional Assessment of Cancer Treatment (FACT)
Changes in Sleep Quality
Patient reported sleep quality is measured by the Pittsburgh Sleep Quality Index (PSQI) questionaire.
Changes in Anxiety and Depression
Patient reported Anxiety and Depression is measured by the Hospital Anxiety and Depression Scale (HADS).
Changes in Physical Activity level
Patient reported physical activity is measured by the International Physical Activity Questionaire (IPAQ) - short form.
T-cell infiltration
T-cell infiltration will be quantified using histological analyses.

Full Information

First Posted
October 28, 2016
Last Updated
December 16, 2019
Sponsor
Rigshospitalet, Denmark
search

1. Study Identification

Unique Protocol Identification Number
NCT02954783
Brief Title
PROstaTe Cancer - Exercise-STudy (PRO-TEST)
Acronym
PRO-TEST
Official Title
Effect of Different Exercise Regimens on Intratumoral Natural Killer (NK) Cell Variability in Men With Localized Prostate Cancer Undergoing Radical Prostatectomy - a Randomized Controlled Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
December 2019
Overall Recruitment Status
Completed
Study Start Date
November 2016 (undefined)
Primary Completion Date
December 2019 (Actual)
Study Completion Date
December 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rigshospitalet, Denmark

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Background and purpose: The purpose of this study is to investigate the effect of exercise on intratumoral natural killer (NK)-cell variability in patients with localized prostate cancer undergoing radical prostatectomy. The primary hypothesis is that exercise induces epinephrine-mediated intratumoral natural killer (NK)-cell infiltration in patients with localized prostate cancer, and that the infiltration is greater in patients performing High Intensity Interval Training compared to usual care controls. Currently there is a lack of randomized controlled trials examining different types of exercise in patients with localized prostate cancer. Moreover there is a need for studies including biological measurements to allow a full assessment of the effect of exercise on diverse biomarkers and mechanistic pathways, which may influence cancer survival. Subjects: Patients with histologically verified prostate adenocarcinoma scheduled for radical prostatectomy at Urologic Department, Rigshospitalet, Copenhagen, Denmark. Methods: In this randomized controlled pilot study 30 patients with localized prostate cancer undergoing radical prostatectomy will be included and randomized 2:1 to either High Intensity Interval Training (HIIT) exercise intervention or observational control receiving usual care from inclusion and until planned surgery (radical prostatectomy). All patients will undergo assessments at inclusion (baseline) and at follow-up after the exercise intervention period (maximum 8 weeks) 3-5 days prior to surgery. Assessments include: anthropometrics; blood pressure; resting hearth rate; cardiorespiratory fitness by cardiopulmonary exercise test (VO2 peak.); body composition by DXA scan; quality of life by self-report questionnaires; fasting blood sample measuring cholesterol, triglycerides, insulin, c-peptide, HbA1c, glucose, hormones and inflammatory markers. Biological tissue from tumor (primary prostate biopsies) will be retrieved from the respective local pathological departments and from the perioperative prostate specimen and sent to protocol analyses.
Detailed Description
The purpose of this study is to investigate the effect of exercise on the variability of intratumoral Natural Killer (NK)-cell infiltration in tumor biopsies taken before and after an exercise intervention in patients randomized 2:1 to one of two study arms: I) High Intensity Interval Training (HIIT) (N=20) or II) usual care, prior to radical prostatectomy. In addition to this the investigators wish to investigate the effect of HIIT exercise on the infiltration of other immune cells into the tumor, tumor vessel morphology, modulation of tumor-metabolism, -biology and signaling. Finally the aim is to explore the effect of pre-operative HIIT exercise on physiological (e.g. cardiovascular fitness, body composition, metabolic profile and metabolic inflammatory markers) and psycho-social (e.g. fatigue, emotional well-being, anxiety) endpoints relative to usual care.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostate Cancer
Keywords
Prostate cancer, Localized, Exercise, Physical activity, Natural killer cells, Immune cells

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
High Intensity Interval Training
Arm Type
Experimental
Arm Description
The HIIT-group will receive usual care plus a supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes.
Arm Title
Usual Care Observational Control
Arm Type
Active Comparator
Arm Description
Patients randomized to usual care control will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.
Intervention Type
Behavioral
Intervention Name(s)
High Intensity Interval Training
Intervention Description
Supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes. Patients will perform a test of maximum cardio-respiratory (VO2 peak test). Using the patient's individual wattmax, a personalized exercise program will be prescribed. After a light warm-up, patients will perform 25 min of aerobic high intensity interval training on a stationary bicycle, intervals will consist of cycles of HI intervals with 120% of wattmax for 1 min followed by recovery for 3 min at 30% of wattmax. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load.
Intervention Type
Behavioral
Intervention Name(s)
Usual Care Observational Control
Intervention Description
The reference group will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.This includes information regarding smoking cessation and alcohol reduction and a physiotherapist consultation regarding pelvic floor exercises. This group is allowed to exercise on their own initiative or participate in any standard care hospital- or municipality-based exercise program. This will be monitored by self-report.
Primary Outcome Measure Information:
Title
Variability in intratumoral Natural Killer (NK)-cell infiltration
Description
Natural killer (NK)-cell infiltration will be quantified using histological analyses.
Time Frame
Primary prostate biopsies and up to 8 weeks
Secondary Outcome Measure Information:
Title
Tumor vessel morphology
Description
Tumor vessel morphology will be evaluated using histological analyses.
Time Frame
Primary prostate biopsies and up to 8 weeks
Title
Tumor-metabolism, - biology and signaling
Description
Tumor samples will undergo proteomic analyzes in order to uncover potential upregulated biomarkers.
Time Frame
Primary prostate biopsies and up to 8 weeks
Title
Changes in immune cells
Description
Quantification of immune cells will be measured in blood samples by flowcytometry analyses.
Time Frame
Baseline and up to 8 weeks
Title
Changes in epinephrine concentration
Description
Concentrations of epinephrine will be measured in blood samples by radioimmunoassay analyses.
Time Frame
Baseline and up to 8 weeks
Title
Changes in nor-epinephrine concentration
Description
Concentrations of nor-epinephrine will be measured in blood samples by radioimmunoassay analyses.
Time Frame
Baseline and up to 8 weeks
Title
Changes in IL-1 concentration
Description
Concentrations of IL-1 (Interleukin 1) will be measured in blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
Time Frame
Baseline and up to 8 weeks
Title
Changes in IL- 2 concentration
Description
Concentrations of IL-2 (Interleukin 2) will be measured in fasting blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
Time Frame
Baseline and up to 8 weeks
Title
Changes in IL- 6 concentration
Description
Concentrations of IL-6 (Interleukin 6) will be measured in fasting blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
Time Frame
Baseline and up to 8 weeks
Title
Changes in IL- 8 concentration
Description
Concentrations of IL-8 (Interleukin 8) will be measured in fasting blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
Time Frame
Baseline and up to 8 weeks
Title
Changes in IL- 10 concentration
Description
Concentrations of IL-10 (Interleukin 10) will be measured in fasting blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
Time Frame
Baseline and up to 8 weeks
Title
Changes in IL- 15R alpha complex concentration
Description
Concentrations of IL- 15Rα (IL- 15 receptor alpha) complex will be measured in blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
Time Frame
Baseline and up to 8 weeks
Title
Changes in Tumor Necrosis Factor alpha (TNFa) concentration
Description
Concentrations of TNFa will be measured in blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
Time Frame
Baseline and up to 8 weeks
Title
Changes in Interferon Gamma (IFNγ) concentration
Description
Concentrations of IFNγ will be measured in blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
Time Frame
Baseline and up to 8 weeks
Title
Changes in Plasma Total-Cholesterol concentrations
Description
Concentrations of total cholesterol will be measured in fasting blood samples by standard laboratory methods.
Time Frame
Baseline and up to 8 weeks
Title
Changes in Plasma LDL-Cholesterol concentrations
Description
Concentrations of LDL-cholesterol will be measured in fasting blood samples by standard laboratory methods
Time Frame
Baseline and up to 8 weeks
Title
Changes in Plasma HDL-Cholesterol concentrations
Description
Concentrations of HDL-cholesterol will be measured in fasting blood samples by standard laboratory methods
Time Frame
Baseline and up to 8 weeks
Title
Changes in Plasma Triglyceride concentrations
Description
Concentrations of triglycerides will be measured in fasting blood samples by standard laboratory methods
Time Frame
Baseline to and up to 8 weeks
Title
Changes in HbA1C (fasting blood samples)
Description
Concentrations of HbA1C will be measured in fasting blood samples by standard laboratory methods
Time Frame
Baseline and up to 8 weeks
Title
Changes in insulin
Description
Concentrations of Insulin will be measured in fasting blood samples by standard laboratory methods
Time Frame
Baseline and up to 8 weeks
Title
Change in body composition
Description
Body weight and anthropometrics (height, waist and hip circumference) will be assessed using standard procedures. Resting heart rate and blood pressure (Microlife, BPA100) will be determined in a supine position. Body composition (fat mass, bone mass and fat-free mass) and bone mineral density are analyzed by whole-body dual-energy X-ray absorptiometry (DXA) scan (Lunar, Lunar Corporation Madison, Wisconsin, USA). Transverse scans at 1 cm intervals are made from head to toe measuring the absorption of x-ray beams at two different energy levels as these are sent through the body. Since the different chemical compounds in the body absorb the intensity of the X-rays differently, the scan allows for a valid determination of bone mass, fat mass and fat-free/bone-free mass
Time Frame
Baseline and up to 8 weeks
Title
Change in VO2peak
Description
The participants will undergo a maximal graded exercise test on a bicycle ergometer for evaluation of cardiovascular function and determination of the peak oxygen uptake (VO2peak). The test starts with a 5 min warm up at 70 watt (the watts may have to be adjusted to the individual fitness level). Warm up is immediately followed by a 20 watt increase every 1 min until exhaustion. Ventilation and expired gases will be measured during the test via an indirect calorimetric system, and heart rate will be assessed simultaneously.
Time Frame
Baseline and up to 8 weeks
Title
Change in wattmax
Description
The participants will undergo a maximal graded exercise test on a bicycle ergometer for evaluation of cardiovascular function and determination of the maximum watt (wattmax). The test starts with a 5 min warm up at 70 watt (the watts may have to be adjusted to the individual fitness level). Warm up is immediately followed by a 20 watt increase every 1 min until exhaustion. The maximum watt will be calculated.
Time Frame
Baseline and up to 8 weeks
Title
Changes in patient-reported Quality of Life - FACT
Description
Patient reported quality of life is measured by Functional Assessment of Cancer Treatment (FACT)
Time Frame
Baseline and up to 8 weeks
Title
Changes in Sleep Quality
Description
Patient reported sleep quality is measured by the Pittsburgh Sleep Quality Index (PSQI) questionaire.
Time Frame
Baseline up to 8 weeks
Title
Changes in Anxiety and Depression
Description
Patient reported Anxiety and Depression is measured by the Hospital Anxiety and Depression Scale (HADS).
Time Frame
Baseline up to 8 weeks
Title
Changes in Physical Activity level
Description
Patient reported physical activity is measured by the International Physical Activity Questionaire (IPAQ) - short form.
Time Frame
Baseline up to 8 weeks
Title
T-cell infiltration
Description
T-cell infiltration will be quantified using histological analyses.
Time Frame
Primary prostate biopsies from baseline and up to 8 weeks

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pathologically verified localized prostate cancer Eligible for curative radical prostatectomy Exclusion Criteria: Any other known malignancy requiring active treatment Performance status > 1 Ongoing treatment with beta blockers Physical disabilities precluding physical testing and/or exercise Inability to read and understand Danish
Facility Information:
Facility Name
Center for Physical Activity Research, Copenhagen University Hospital
City
Copenhagen
ZIP/Postal Code
DK-2100
Country
Denmark

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

PROstaTe Cancer - Exercise-STudy (PRO-TEST)

We'll reach out to this number within 24 hrs